Murphy Capital Management Inc. reduced its position in shares of Allergan PLC. (NYSE:AGN) by 7.5% during the second quarter, according to its most recent filing with the SEC. The fund owned 3,680 shares of the company’s stock after selling 300 shares during the period. Murphy Capital Management Inc.’s holdings in Allergan PLC. were worth $894,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in AGN. Gillespie Robinson & Grimm Inc. boosted its position in Allergan PLC. by 2.3% in the first quarter. Gillespie Robinson & Grimm Inc. now owns 98,017 shares of the company’s stock worth $23,418,000 after buying an additional 2,174 shares in the last quarter. Douglass Winthrop Advisors LLC boosted its position in Allergan PLC. by 15.6% in the first quarter. Douglass Winthrop Advisors LLC now owns 11,675 shares of the company’s stock worth $2,789,000 after buying an additional 1,574 shares in the last quarter. Charter Trust Co. acquired a new position in Allergan PLC. during the first quarter worth about $213,000. Raymond James Trust N.A. boosted its position in Allergan PLC. by 7.6% in the first quarter. Raymond James Trust N.A. now owns 8,868 shares of the company’s stock worth $2,119,000 after buying an additional 629 shares in the last quarter. Finally, New England Research & Management Inc. boosted its position in Allergan PLC. by 7.1% in the first quarter. New England Research & Management Inc. now owns 2,275 shares of the company’s stock worth $544,000 after buying an additional 150 shares in the last quarter. Hedge funds and other institutional investors own 84.66% of the company’s stock.
Allergan PLC. (NYSE:AGN) traded down 3.08% during midday trading on Friday, hitting $242.65. The stock had a trading volume of 3,014,756 shares. Allergan PLC. has a 12 month low of $184.50 and a 12 month high of $256.80. The firm’s 50-day moving average price is $245.21 and its 200 day moving average price is $237.12. The company has a market cap of $81.50 billion, a P/E ratio of 7.56 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last released its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter last year, the business posted $3.35 EPS. On average, analysts expect that Allergan PLC. will post $16.10 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.15%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s payout ratio is presently 9.95%.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/05/allergan-plc-agn-position-cut-by-murphy-capital-management-inc.html.
A number of research firms have issued reports on AGN. Mizuho reiterated a “buy” rating and issued a $267.00 target price on shares of Allergan PLC. in a research report on Wednesday. Royal Bank Of Canada set a $285.00 price target on Allergan PLC. and gave the company a “buy” rating in a research note on Thursday. Wells Fargo & Company lifted their price target on Allergan PLC. to $278.00 and gave the company an “outperform” rating in a research note on Thursday. Deutsche Bank AG reissued a “buy” rating and set a $273.00 price target (up from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. Finally, Vetr raised Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price target on the stock in a research note on Monday, June 26th. Seven investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Allergan PLC. currently has a consensus rating of “Buy” and a consensus price target of $274.04.
In other news, Director Nesli Basgoz sold 1,889 shares of the firm’s stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.36% of the company’s stock.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.
